[(2R,3S,4S,6S)-4-hydroxy-2-(2-hydroxypropyl)-6-[1,4,8-trihydroxy-13-[3-[(11E,15E,19E)-21-[(2S,3R,5R)-3-hydroxy-5-(2-methylidenepent-4-enyl)oxolan-2-yl]-3-methyl-17-methylidenehenicosa-11,15,19-trienyl]oxiran-2-yl]-6-oxo-10-[(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-[[(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxan-2-yl]oxytridecyl]oxan-3-yl] hydrogen sulfate
| Internal ID | 95c8a2fc-b18c-4859-83c7-a8c4150d2553 |
| Taxonomy | Lipids and lipid-like molecules > Fatty Acyls > Fatty acyl glycosides > Fatty acyl glycosides of mono- and disaccharides |
| IUPAC Name | [(2R,3S,4S,6S)-4-hydroxy-2-(2-hydroxypropyl)-6-[1,4,8-trihydroxy-13-[3-[(11E,15E,19E)-21-[(2S,3R,5R)-3-hydroxy-5-(2-methylidenepent-4-enyl)oxolan-2-yl]-3-methyl-17-methylidenehenicosa-11,15,19-trienyl]oxiran-2-yl]-6-oxo-10-[(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-[[(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxan-2-yl]oxytridecyl]oxan-3-yl] hydrogen sulfate |
| SMILES (Canonical) | |
| SMILES (Isomeric) | |
| InChI | InChI=1S/C68H114O25S/c1-6-21-43(4)32-49-37-51(75)53(87-49)26-19-18-24-41(2)22-16-14-12-10-8-7-9-11-13-15-17-23-42(3)28-31-55-54(89-55)27-20-25-48(88-68-65(82)63(80)61(78)59(92-68)40-86-67-64(81)62(79)60(77)58(39-69)91-67)36-47(73)35-46(72)34-45(71)29-30-50(74)56-38-52(76)66(93-94(83,84)85)57(90-56)33-44(5)70/h6,8,10,16,18-19,22,42,44-45,47-71,73-82H,1-2,4,7,9,11-15,17,20-21,23-40H2,3,5H3,(H,83,84,85)/b10-8+,19-18+,22-16+/t42?,44?,45?,47?,48?,49-,50?,51-,52+,53+,54?,55?,56+,57-,58-,59-,60-,61-,62+,63+,64-,65-,66+,67-,68-/m1/s1 |
| InChI Key | SBQSWWPNOSKPEC-JTHMKMEASA-N |
| Popularity | 3 references in papers |
| Molecular Formula | C68H114O25S |
| Molecular Weight | 1363.70 g/mol |
| Exact Mass | 1362.73699029 g/mol |
| Topological Polar Surface Area (TPSA) | 420.00 Ų |
| XlogP | 5.20 |
| Atomic LogP (AlogP) | 3.99 |
| H-Bond Acceptor | 24 |
| H-Bond Donor | 14 |
| Rotatable Bonds | 47 |
| There are no found synonyms. |
![2D Structure of [(2R,3S,4S,6S)-4-hydroxy-2-(2-hydroxypropyl)-6-[1,4,8-trihydroxy-13-[3-[(11E,15E,19E)-21-[(2S,3R,5R)-3-hydroxy-5-(2-methylidenepent-4-enyl)oxolan-2-yl]-3-methyl-17-methylidenehenicosa-11,15,19-trienyl]oxiran-2-yl]-6-oxo-10-[(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-[[(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxan-2-yl]oxytridecyl]oxan-3-yl] hydrogen sulfate](https://plantaedb.com/storage/docs/compounds/2023/11/3da2bb20-852e-11ee-93e3-07640eca4af0.jpg "2D Structure of [(2R,3S,4S,6S)-4-hydroxy-2-(2-hydroxypropyl)-6-[1,4,8-trihydroxy-13-[3-[(11E,15E,19E)-21-[(2S,3R,5R)-3-hydroxy-5-(2-methylidenepent-4-enyl)oxolan-2-yl]-3-methyl-17-methylidenehenicosa-11,15,19-trienyl]oxiran-2-yl]-6-oxo-10-[(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-[[(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxan-2-yl]oxytridecyl]oxan-3-yl] hydrogen sulfate")
| Target | Value | Probability (raw) | Probability (%) |
|---|---|---|---|
| Human Intestinal Absorption | + | 0.5826 | 58.26% |
| Caco-2 | - | 0.8614 | 86.14% |
| Blood Brain Barrier | + | 0.5750 | 57.50% |
| Human oral bioavailability | - | 0.8000 | 80.00% |
| Subcellular localzation | Mitochondria | 0.5759 | 57.59% |
| OATP2B1 inhibitior | - | 1.0000 | 100.00% |
| OATP1B1 inhibitior | + | 0.8089 | 80.89% |
| OATP1B3 inhibitior | + | 0.9364 | 93.64% |
| MATE1 inhibitior | - | 0.9612 | 96.12% |
| OCT2 inhibitior | - | 0.8000 | 80.00% |
| BSEP inhibitior | + | 0.9814 | 98.14% |
| P-glycoprotein inhibitior | + | 0.7398 | 73.98% |
| P-glycoprotein substrate | + | 0.8167 | 81.67% |
| CYP3A4 substrate | + | 0.7557 | 75.57% |
| CYP2C9 substrate | - | 1.0000 | 100.00% |
| CYP2D6 substrate | - | 0.8691 | 86.91% |
| CYP3A4 inhibition | - | 0.7170 | 71.70% |
| CYP2C9 inhibition | - | 0.7314 | 73.14% |
| CYP2C19 inhibition | - | 0.6896 | 68.96% |
| CYP2D6 inhibition | - | 0.8622 | 86.22% |
| CYP1A2 inhibition | - | 0.7164 | 71.64% |
| CYP2C8 inhibition | + | 0.8253 | 82.53% |
| CYP inhibitory promiscuity | - | 0.9126 | 91.26% |
| UGT catelyzed | + | 0.6000 | 60.00% |
| Carcinogenicity (binary) | - | 0.5700 | 57.00% |
| Carcinogenicity (trinary) | Non-required | 0.5922 | 59.22% |
| Eye corrosion | - | 0.9744 | 97.44% |
| Eye irritation | - | 0.8991 | 89.91% |
| Skin irritation | - | 0.7478 | 74.78% |
| Skin corrosion | - | 0.9019 | 90.19% |
| Ames mutagenesis | - | 0.6078 | 60.78% |
| Human Ether-a-go-go-Related Gene inhibition | + | 0.8399 | 83.99% |
| Micronuclear | + | 0.5800 | 58.00% |
| Hepatotoxicity | - | 0.5625 | 56.25% |
| skin sensitisation | - | 0.8188 | 81.88% |
| Respiratory toxicity | + | 0.5222 | 52.22% |
| Reproductive toxicity | + | 0.7111 | 71.11% |
| Mitochondrial toxicity | + | 0.6125 | 61.25% |
| Nephrotoxicity | - | 0.6791 | 67.91% |
| Acute Oral Toxicity (c) | III | 0.5776 | 57.76% |
| Estrogen receptor binding | + | 0.8196 | 81.96% |
| Androgen receptor binding | + | 0.7281 | 72.81% |
| Thyroid receptor binding | + | 0.6046 | 60.46% |
| Glucocorticoid receptor binding | + | 0.7505 | 75.05% |
| Aromatase binding | + | 0.5735 | 57.35% |
| PPAR gamma | + | 0.8093 | 80.93% |
| Honey bee toxicity | - | 0.6079 | 60.79% |
| Biodegradation | - | 0.8250 | 82.50% |
| Crustacea aquatic toxicity | - | 0.6300 | 63.00% |
| Fish aquatic toxicity | + | 0.9919 | 99.19% |
Proven Targets:
| CHEMBL ID | UniProt ID | Name | Min activity | Assay type | Source |
|---|---|---|---|---|---|
| No proven targets yet! | |||||
Predicted Targets (via Super-PRED):
| CHEMBL ID | UniProt ID | Name | Probability | Model accuracy |
|---|---|---|---|---|
| CHEMBL220 | P22303 | Acetylcholinesterase | 99.69% | 94.45% |
| CHEMBL3130 | O00329 | PI3-kinase p110-delta subunit | 98.01% | 96.47% |
| CHEMBL218 | P21554 | Cannabinoid CB1 receptor | 96.08% | 96.61% |
| CHEMBL2581 | P07339 | Cathepsin D | 95.51% | 98.95% |
| CHEMBL3267 | P48736 | PI3-kinase p110-gamma subunit | 95.40% | 95.71% |
| CHEMBL3251 | P19838 | Nuclear factor NF-kappa-B p105 subunit | 95.33% | 96.09% |
| CHEMBL4588 | P22894 | Matrix metalloproteinase 8 | 95.20% | 94.66% |
| CHEMBL3060 | Q9Y345 | Glycine transporter 2 | 94.93% | 99.17% |
| CHEMBL5619 | P27695 | DNA-(apurinic or apyrimidinic site) lyase | 94.75% | 91.11% |
| CHEMBL3145 | P42338 | PI3-kinase p110-beta subunit | 94.67% | 98.75% |
| CHEMBL4793 | Q86TI2 | Dipeptidyl peptidase IX | 93.67% | 96.95% |
| CHEMBL4657 | Q6V1X1 | Dipeptidyl peptidase VIII | 93.48% | 97.21% |
| CHEMBL3892 | Q99500 | Sphingosine 1-phosphate receptor Edg-3 | 93.41% | 97.29% |
| CHEMBL253 | P34972 | Cannabinoid CB2 receptor | 93.25% | 97.25% |
| CHEMBL5255 | O00206 | Toll-like receptor 4 | 92.72% | 92.50% |
| CHEMBL2072 | P35499 | Sodium channel protein type IV alpha subunit | 92.49% | 92.32% |
| CHEMBL1907603 | Q05586 | Glutamate NMDA receptor; GRIN1/GRIN2B | 92.35% | 95.89% |
| CHEMBL1806 | P11388 | DNA topoisomerase II alpha | 92.04% | 89.00% |
| CHEMBL3401 | O75469 | Pregnane X receptor | 91.56% | 94.73% |
| CHEMBL4203 | Q9HAZ1 | Dual specificity protein kinase CLK4 | 91.30% | 94.45% |
| CHEMBL340 | P08684 | Cytochrome P450 3A4 | 90.75% | 91.19% |
| CHEMBL4187 | Q99250 | Sodium channel protein type II alpha subunit | 90.39% | 95.50% |
| CHEMBL3137262 | O60341 | LSD1/CoREST complex | 90.33% | 97.09% |
| CHEMBL2730 | P21980 | Protein-glutamine gamma-glutamyltransferase | 89.97% | 92.38% |
| CHEMBL2179 | P04062 | Beta-glucocerebrosidase | 89.92% | 85.31% |
| CHEMBL1293267 | Q9HC97 | G-protein coupled receptor 35 | 89.90% | 89.34% |
| CHEMBL4303 | P08238 | Heat shock protein HSP 90-beta | 89.62% | 96.77% |
| CHEMBL3108638 | O15164 | Transcription intermediary factor 1-alpha | 88.93% | 95.56% |
| CHEMBL4302 | P08183 | P-glycoprotein 1 | 88.54% | 92.98% |
| CHEMBL1075094 | Q16236 | Nuclear factor erythroid 2-related factor 2 | 88.31% | 96.00% |
| CHEMBL1293316 | Q9HBX9 | Relaxin receptor 1 | 87.82% | 82.50% |
| CHEMBL3392948 | Q9NP59 | Solute carrier family 40 member 1 | 87.04% | 95.00% |
| CHEMBL4361 | Q07820 | Induced myeloid leukemia cell differentiation protein Mcl-1 | 86.94% | 95.52% |
| CHEMBL5163 | Q9NY46 | Sodium channel protein type III alpha subunit | 86.79% | 96.90% |
| CHEMBL1907602 | P06493 | Cyclin-dependent kinase 1/cyclin B1 | 86.00% | 91.24% |
| CHEMBL2274 | Q9H228 | Sphingosine 1-phosphate receptor Edg-8 | 85.71% | 100.00% |
| CHEMBL3476 | O15111 | Inhibitor of nuclear factor kappa B kinase alpha subunit | 85.31% | 95.83% |
| CHEMBL2111367 | P27986 | PI3-kinase p110-alpha/p85-alpha | 83.80% | 94.33% |
| CHEMBL3359 | P21462 | Formyl peptide receptor 1 | 83.69% | 93.56% |
| CHEMBL5103 | Q969S8 | Histone deacetylase 10 | 83.22% | 90.08% |
| CHEMBL2514 | O95665 | Neurotensin receptor 2 | 83.15% | 100.00% |
| CHEMBL2955 | O95136 | Sphingosine 1-phosphate receptor Edg-5 | 82.69% | 92.86% |
| CHEMBL4015 | P41597 | C-C chemokine receptor type 2 | 82.14% | 98.57% |
| CHEMBL3004 | P33527 | Multidrug resistance-associated protein 1 | 81.78% | 96.37% |
| CHEMBL1993 | P26358 | DNA (cytosine-5)-methyltransferase 1 | 81.11% | 95.44% |
| CHEMBL4073 | P09237 | Matrix metalloproteinase 7 | 80.95% | 97.56% |
| CHEMBL3430907 | Q96GD4 | Aurora kinase B/Inner centromere protein | 80.19% | 97.50% |
Below are displayed all the plants proven (via scientific papers) to contain this
compound!
To see more specific details click the taxa you are interested in.
To see more specific details click the taxa you are interested in.
| There are no matching plants. |
| PubChem | 101005030 |
| LOTUS | LTS0171407 |
| wikiData | Q105249618 |